These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3196876)

  • 21. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
    Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
    Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VAD followed by VMCP: an alternative regimen for multiple myeloma.
    Wadhwa J; Kumar L; Kochupillai V
    Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
    Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
    Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
    Raaijmakers HG; Izquierdo MA; Lokhorst HM; de Leeuw C; Belien JA; Bloem AC; Dekker AW; Scheper RJ; Sonneveld P
    Blood; 1998 Feb; 91(3):1029-36. PubMed ID: 9446666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
    Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
    Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
    Bladé J; Rosiñol L; Sureda A; Ribera JM; Díaz-Mediavilla J; García-Laraña J; Mateos MV; Palomera L; Fernández-Calvo J; Martí JM; Giraldo P; Carbonell F; Callís M; Trujillo J; Gardella S; Moro MJ; Barez A; Soler A; Font L; Fontanillas M; San Miguel J;
    Blood; 2005 Dec; 106(12):3755-9. PubMed ID: 16105975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
    Mineur P; Ménard JF; Le Loët X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C; De Gramont A; Wetterwald M; Euller-Ziegler L; Peny AM; Monconduit M; Michaux JL
    Br J Haematol; 1998 Nov; 103(2):512-7. PubMed ID: 9827927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
    Lokhorst HM; van der Holt B; Zweegman S; Vellenga E; Croockewit S; van Oers MH; von dem Borne P; Wijermans P; Schaafsma R; de Weerdt O; Wittebol S; Delforge M; Berenschot H; Bos GM; Jie KS; Sinnige H; van Marwijk-Kooy M; Joosten P; Minnema MC; van Ammerlaan R; Sonneveld P;
    Blood; 2010 Feb; 115(6):1113-20. PubMed ID: 19880501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose glucocorticoid treatment of resistant myeloma.
    Alexanian R; Barlogie B; Dixon D
    Ann Intern Med; 1986 Jul; 105(1):8-11. PubMed ID: 3717812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
    Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of multiple myeloma.
    Alexanian R; Dimopoulos M
    N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.